US Biosimilars See A Banner Year Despite Few Approvals
Multiple Products Compete On Key Molecules As Insulins Make Transition
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
You may also be interested in...
AmerisourceBergen’s senior director of biosimilars, Sean McGowan, believes that momentum is continuing to build for US biosimilars in 2021, especially with key developments involving insulins and interchangeability on the horizon.
Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.